PB1849: EARLY SALVAGE THERAPY WITH VENETOCLAX AND 10-DAY DECITABINE IS FEASIBLE AND SAFE IN REFRACTORY AML: RESULTS FROM 11 PATIENTS WITH EARLY INDUCTION FAILURE

• Carla Borst,
• Franziska Ginsberg,
• Jan Weller,
• Wichard Vogel,
• Christoph Faul,
• Wolfgang Bethge,
• Maximilian Christopeit,
• Claudia Lengerke

Affiliations

Carla Borst

1 Universitätsklinik Tübingen, Hematology/Oncology, Tübingen, Germany

Franziska Ginsberg

1 Universitätsklinik Tübingen, Hematology/Oncology, Tübingen, Germany

Jan Weller

1 Universitätsklinik Tübingen, Hematology/Oncology, Tübingen, Germany

Wichard Vogel

1 Universitätsklinik Tübingen, Hematology/Oncology, Tübingen, Germany

Christoph Faul

1 Universitätsklinik Tübingen, Hematology/Oncology, Tübingen, Germany

Wolfgang Bethge

1 Universitätsklinik Tübingen, Hematology/Oncology, Tübingen, Germany

Maximilian Christopeit

1 Universitätsklinik Tübingen, Hematology/Oncology, Tübingen, Germany

Claudia Lengerke

1 Universitätsklinik Tübingen, Hematology/Oncology, Tübingen, Germany